Al Sandrock (Biogen via YouTube)
July 27, 2021 07:42 AM EDTUpdated 07:53 AM
R&D

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

Amber Tong

Even as Bio­gen ex­ecs scram­bled to de­fend Aduhelm and paint a rosy fu­ture the drug promis­es to un­leash, R&D chief Al San­drock re­as­sured an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times